- Home
- ABEO vs FHTX Comparison
ABEO vs FHTX Comparison
Compare ABEO & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | FHTX |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.3M | 323.4M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABEO | FHTX |
|---|---|---|
| Price | $6.36 | $5.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $20.00 | $11.50 |
| AVG Volume (30 Days) | ★ 1.3M | 218.7K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | $2,998,000.00 | ★ $30,909,000.00 |
| Revenue This Year | $1,024.31 | $8.89 |
| Revenue Next Year | $145.42 | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | 36.75 |
| 52 Week Low | $4.00 | $3.27 |
| 52 Week High | $7.54 | $6.95 |
Technical Indicators
Market Signals| Indicator | ABEO | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.60 | 75.33 |
| Support Level | $5.19 | $5.22 |
| Resistance Level | N/A | $5.84 |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 97.81 | 97.10 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.